ISS and Glass Lewis recommend Ikena stockholders vote FOR Inmagene merger

ImageneBio, Inc.

Institutional Shareholder Services (ISS) and Glass Lewis recommend voting FOR share issuance related to merger with Inmagene.
Ikena's Annual Meeting is July 15, 2025; record date was May 22, 2025.
Inmagene's lead candidate is IMG-007, a nondepleting anti-OX40 mAb for immune & inflammatory diseases.
CEO Mark Manfredi cited IMG-007's potential to build shareholder value in I&I space.
Proxy includes seven proposals; all votes are important for merger approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.